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the long-term status of body energy stores. Although
these long and short-term signals have often been
viewed as operating independently, it now appears that
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Beth Israel Deaconess Medical Center they functionally overlap. Both converge on brain cen-
ters, most importantly within the hypothalamus, whereBoston, Massachusetts 02215
the signals are integrated, and the direction and magni-
tude of efferent responses are determined. The efferent
elements of the physiologic system include those regu-The worldwide prevalence of obesity is increasing at
an alarming rate, with major adverse consequences lating the intensity of hunger and subsequent food seek-
ing behavior, the level of energy expenditure, includingfor human health. This “obesity epidemic” is paralleled
by a rapid and substantive increase in our understand- basal and that determined by physical activity, the levels
of key circulating hormones such as insulin and gluco-ing of molecular pathways and physiologic systems
underlying the regulation of energy balance. While corticoids, and to a much smaller degree factors that
influence the relative sizes of lean and fat mass in theefforts to address the environmental factors that are
responsible for the recent “epidemic” must continue, body. Some of these same signals also regulate pro-
cesses such as reproduction and growth that are linkednew molecular and physiologic insights into this sys-
tem offer exciting possibilities for future development to nutritional sufficiency (Figure 1).
Since survival is more acutely threatened by starva-of successful therapies.
tion than obesity, it should come as no surprise that
this system is more robustly organized to galvanize inThe past ten years have been the golden age of obesity
response to deficient energy intake and stores than toresearch. While long understood that the amount of
excess energy (Ahima et al., 1996). Indeed, the efficientbody weight and fat are determined by an interplay of
storage of energy as fat promotes survival when foodinheritance and environment, we are for the first time
supplies are scarce, and evolution would be expected tolearning the identity of some of the responsible genes.
favor such “thrifty genotypes” (Neel, 1999). Nonetheless,Not surprisingly, the protein products of these genes
increased energy stores promote adaptive responsesdefine critical physiologic pathways for the regulation
that resist obesity in experimental animals and humans.of energy balance. Among the most consequential dis-
These “obesity avoidance” responses are characterizedcoveries were the ob gene product leptin (Zhang et al.,
by suppression of appetite and increased energy expen-1994) and the leptin receptor, the latter first reported in
diture (Weigle, 1994), and involve the same effectorCell in 1995 (Tartaglia et al., 1995). These discoveries
mechanisms that respond in an opposite direction toand others have transformed a former research back-
starvation, as though a switch can be thrown from star-water into a hotbed of modern science and drug discov-
vation avoidance to obesity avoidance modes de-ery. It seems likely that insights into weight-regulatory
pending on the environment. Unfortunately, circuits thatpathways will accelerate identification of molecular tar-
suppress appetite and increase energy expenditure ingets that will eventually produce safe and effective phar-
response to obesity-promoting aspects of the currentmaceuticals for obesity and its complications. However,
environment are insufficiently robust to prevent obesitytherapeutic optimism is occurring not a moment too
and its complications in a large and increasing fractionsoon, as an epidemic of obesity rages on, oblivious to
of the population. On the other hand, many individualsthese scientific achievements. Why is this happening?
do resist obesity despite exposure to a common “toxic”Obesity-promoting changes in our diet and reduced
environment. The variable susceptibility to obesity inphysical activity are accelerating on a global scale, out-
response to environmental influences is undoubtedlypacing scientific progress. Nevertheless, many individu-
modulated by specific genes. Existing knowledge at thisals manage to resist obesity. Accordingly, a key goal of
interface is still fragmentary and is likely to be an areafuture research must be to identify mechanisms by which
of great future progress.environmental factors interact with specific genes, either
to promote, or facilitate resistance to obesity.
Leptin and Energy Balance
Overview of Regulated Energy Balance Eight years after the positional cloning of the ob gene
Over the past decade, we have reached consensus that (Zhang et al., 1994) and the subsequent discovery that
a physiologic system exists, the prime function of which the encoded protein, leptin, is an adipocyte-derived cy-
is to maintain homeostasis of energy stores in response tokine whose administration reverses obesity caused
to variable access to nutrition and demands for energy by leptin deficiency in mice (Halaas et al., 1995) and
expenditure. This system has both afferent sensing humans (Farooqi et al., 1999), the biological role of leptin
components, and efferent effector limbs. The afferent continues to be actively explored. Leptin was initially
limb of this system includes several kinds of signals. viewed as an adipocyte-derived signal that functioned
One reflects short-term events such as those related to primarily to prevent obesity, and that was the basis for
onset or termination of individual meals; another senses its being named leptin, from the Greek root leptos for
thin (Halaas et al., 1995). It is now understood that leptin
also serves as an important signal from fat to brain*Correspondence: jflier@bidmc.harvard.edu
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Figure 1. Components of the Energy Balance System
The energy balance system involves long-term afferent signals from fat (leptin) and pancreatic  cells (insulin) and short-term, meal-related
afferent signals from the gut, including inhibitors of feeding (PYY, GLP-1, and CCK), and the stimulator of feeding (ghrelin). These inputs are
integrated within the brain. Efferent outputs regulate appetite, energy expenditure, hormonal milieu, energy partitioning, and the status of
reproduction and growth.
informing the brain, by its suppression, that the body is suppressed by therapy with recombinant leptin. (Fa-
rooqi et al., 2002).starving (Ahima et al., 1996), and this function is likely
to be as important, or more important, than its antiobe- Is there a syndrome of partial leptin deficiency, more
common than the extremely rare homozygous loss ofsity role. In the absence of leptin, the brain senses star-
vation despite massive obesity. Leptin deficiency drives function mutants of leptin or its receptor? Relatives of
the leptin-deficient patients who are heterozygous forhunger, suppresses energy expenditure, and inhibits re-
productive competence, all advantageous adaptations leptin deficiency do have a phenotype, comprising mod-
est obesity and leptin levels below that expected forin the context of starvation. The most sensitive area of
the leptin dose response curve resides between the low their increased fat mass (Farooqi et al., 2001). Such
individuals will likely respond to leptin therapy withlevels brought about by food restriction (starvation) and
the rising levels induced by refeeding. Additional effects weight loss, although this has not yet been reported. In
patients with ordinary obesity, leptin levels are in-of very high leptin levels that develop with obesity are
at best of modest magnitude, and resistance to the creased in proportion to body fat (Considine et al., 1996),
and this hyperleptinemia, together with the meager re-action of leptin to suppress body weight is prone to
develop in many individuals. sponse of body weight in such individuals to therapeutic
recombinant leptin (Heymsfield et al., 1999), defines aSome important differences between mice and hu-
mans deficient in leptin are now apparent. Leptin defi- state of leptin resistance. Despite this correlation be-
tween fat mass and leptin level in populations, leptincient mice have clearly reduced energy expenditure and
efficient metabolism such that obesity develops even levels in individuals with the same degree of obesity can
vary widely, suggesting that a subpopulation might havewithout overeating. In contrast, efficient metabolism has
not yet been documented in several totally leptin defi- relative leptin deficiency, which might predict leptin re-
sponsive obesity. Studies with recombinant leptin havecient humans; hyperphagia appears to be the sole or
dominant factor (Farooqi et al., 2002). Likewise, leptin to date provided no direct evidence for this hypothesis.
deficient mice have a marked activation of the hypothal-
amic-pituitary-adrenal (stress) axis that contributes to Leptin Resistance
The mechanism for resistance to the weight reducingthe obese and diabetic phenotypes, but this is not ob-
served in leptin deficient humans (Farooqi et al., 2002). effects of leptin in most obesity has received consider-
able attention, but is still unclear eight years after theDespite these species differences, mice and humans
deficient in leptin are united by markedly increased ap- first identification of the leptin receptor (Tartaglia et al.,
1995). Two general molecular mechanisms have beenpetite and consequent obesity, plus failure to initiate
puberty; both of these abnormalities are dramatically identified. The first may involve a defect in leptin trans-
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port across the blood brain barrier, to sites of action duction is maintained in usual obesity, but absent when
within the CNS critical for leptin regulation of energy receptors are absent. There is therefore increased inter-
balance. The existence of a transport defect is sup- est in the precise signaling pathways downstream of
ported by the enhanced potency of leptin administered the leptin receptor that mediate its actions on energy
within the brain (as opposed to peripherally) in a mouse balance and endocrine function. Initial attention focused
model of diet-induced obesity (Van Heek et al., 1997). on the JAK STAT pathway, and consequent regulation
Short isoforms of the leptin receptor lacking the se- of gene expression. However, additional pathways down-
quences required for STAT activation, such as the origi- stream of JAK, including MAP kinase and PI3 kinase,
nal species cloned by Tartaglia et al. in 1995, are ex- are capable of being activated by leptin in vitro and in
pressed at high levels in brain microvessels of mice, vivo (Kim et al., 2000). Recently, a knockin mouse has
and contribute to leptin transport into the CNS (Hileman been created (Lepr Y1138S) in which the leptin receptor
et al., 2002). Whether the Vmax of leptin transport is is incapable of activating STAT 3, but retains ability to
inherently inadequate (in some or all obese individuals) activate other pathways downstream of JAK (Bates et
to permit high leptin levels to act at certain sites within al., 2003). The resulting mouse has severe obesity and
the CNS, or an initially effective transport process be- many other features of complete leptin resistance seen
comes impeded by unknown nutritional or environmen- in leprdb/db mice with mutation of the leptin receptor gene,
tal factors is as yet unclear. It is also unresolved to what but interestingly this mouse has preserved reproductive
degree leptin action in specific regions of the hypothala- capacity, suggesting that some actions downstream of
mus or extra-hypothalamic brain requires transport the leptin receptor employ signaling pathways indepen-
across the blood brain barrier (BBB). Some important dent of STAT 3. Studies with enzyme inhibitors suggest
leptin target neurons in the arcuate nucleus (vide infra) that PI3 kinase may be necessary for some of the actions
are thought to reside outside the BBB, directly exposed of leptin on food intake (Niswender et al., 2003). Actions
to the peripheral circulation. To the extent that these of leptin to suppress appetite and regulate endocrine
sites are key loci of leptin action, a defective leptin trans- function may therefore involve both PI3 kinase and
port mechanism should not be important. On the other STAT3 signaling, as well as other pathways as yet unde-
hand, it is possible that the importance, in isolation, of fined.
these target sites in the arcuate nucleus, or their expo-
sure to the peripheral circulation, have been overesti- A Role for Insulin in Energy Balance?
mated. Is leptin the only peripheral hormone whose levels fall
The long isoform of the leptin receptor, known as to signal starvation, and rise in proportion to increasing
ObRb, is a potent activator of JAK/STAT signaling (Vaisse obesity to limit weight gain? The extreme obesity of
et al., 1996). In normal mice exposed to high fat diets leptin deficiency indicates that lack of leptin cannot be
that promote obesity, the ability of leptin to activate substantially compensated by other hormonal signals.
STAT3 in hypothalamus is diminished (El-Haschimi et On the other hand, other less potent signals might co-
al., 2000). Potential mechanisms for suppression of exist with leptin and play a role in energy balance. Insulin
proximal leptin signaling have therefore been sought.
is a product of the pancreatic  cells and is the master
SOCS3 is an antagonist of leptin signaling that is rapidly
metabolic switch between the fed and fasted states as
induced within key hypothalamic neurons in a leptin
relates to metabolic fuel disposition and use. Its levels
dependent manner (Bjorbaek et al., 1999). Although
are well known to fall with fasting, and rise with obesity,there are suggestions that SOCS3 expression is induced
similar to leptin. This led to the proposal many yearsin some tissues in models of nutritional or age-associ-
before the cloning of the ob gene, that insulin might beated obesity (Wang et al., 2000), the role of this factor
the dominant signal of fuel status to the brain (Woodsin the etiology of obesity has been difficult to resolve
et al., 1985). A transport system of insulin across thewith certainty through genetic approaches, as Socs3/
BBB was described, and administration of pharmaco-mice are embryonic lethal. Other approaches to creating
logic doses of insulin within the CNS suppresses foodSOCS3 deficiency in order to assess the effect on weight
intake in rodents and subhuman primates, and regulatesregulation and leptin action are needed. Recent studies
expression of hypothalamic neuropeptides that influ-indicate that haploinsufficiency of SOCS3 creates mice
ence appetite (Schwartz et al., 2000). The discovery ofthat are more sensitive to leptin, and resistant to obesity
leptin put this subject on the back burner, but insulin isand its metabolic complications produced by high fat
receiving renewed attention. Targeted deletion of thediet (B.J.C., J.K.H., L.O., I.T., C.B., and J.S.F., unpub-
insulin receptor in neurons produces obesity in micelished data). PTP1b is another candidate regulator of
(Bruning et al., 2000), but this is very mild compared toleptin sensitivity. Mice deficient in this tyrosine phospha-
the severe obesity that develops when leptin receptorstase have increased insulin sensitivity, and also resist
are deleted from neurons (Cohen et al., 2001). Interest-obesity, and PTP1b deficient mice are more sensitive
ingly, suppression of insulin signaling within the brainto leptin, possibly by enhanced JAK kinase activity (Za-
using antisense reduces the ability of peripherally ad-bolotny et al., 2002; Cheng et al., 2002). Whether SOCS3
ministered insulin to suppress hepatic glucose produc-and PTP1b have additive effects to suppress leptin sig-
tion (Obici et al., 2002b). Insulin had been thought tonaling has not yet been evaluated.
exert its actions on the liver directly on peripheral or-Although resistance to leptin action on body weight
gans. Thus, CNS insulin receptors may influence bothand STAT3 signaling are seen in typical obesity, it is
energy balance and peripheral metabolic pathways, per-clear that this is both less severe than that seen in rare
haps through signaling in key integrative neurons thatcases where the receptor is totally lacking, and less
global, since the leptin signal required to maintain repro- also respond to leptin and other signals. Since rats with
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Figure 2. The Adipocyte as an Endocrine Cell
In addition to releasing free fatty acids (FFA) which can function as fuels or signals, adipocytes can modify steroid hormones leading to
production of estrogen and glucocorticoids, and release an increasing number of hormones, hormone precursors, hemostatic regulators, or
cytokines including leptin, angiotensinogen, plasminogen activator inhibitor-1 (PAI-1), TNF-, IL-6, resistin, adiponectin, and complement
factor D, also known as adipsin.
mutations in the leptin receptor gene have a reduced ated by both neural pathways and direct actions on
peripheral tissues (Minokoshi et al., 2002).response to insulin administered centrally, leptin action
may influence insulin action pathways in the brain. The disorders of lipoatrophy, in which fat tissue fails
to develop or is lost, have produced valuable insights
into the mechanism for metabolic dysfunction that ac-
Direct Actions of Leptin Outside of the Brain company leptin deficiency. Mice develop lipoatrophy
Many actions of leptin are exerted initially through bind- when a truncated version of the nuclear protein SREBP-
ing to receptor sites on specific hypothalamic neurons, 1c is transgenically expressed in adipose tissue (Shimo-
after which peripheral actions are exerted through con- mura et al., 1999). The insulin resistance and diabetes
sequences of reduced food intake, or changes in secre- seen in these mice was reversed by recombinant leptin
tion of pituitary hormones and autonomic nerve activity. (Shimomura et al., 1999), supporting the view that defi-
However, the long, signaling form of the leptin receptor cient leptin caused by loss of its tissue of origin, is a
(ObRb) is also expressed in many peripheral tissues, major cause of this metabolic defect. Recombinant lep-
including liver, fat, heart,  cells of the pancreas, and tin therapy in patients with congenital lipodystrophy has
immune cells. Several approaches have been employed also been shown to ameliorate insulin resistance, as
to demonstrate that leptin can signal directly in periph- well as reduce the accumulation of lipid within many
eral cells, and the actions of leptin through such direct tissues other than fat (Oral et al., 2002). To what extent
pathways may reverse some phenotypes of leptin defi- these actions are mediated via the CNS or involve direct
ciency, such as by promoting dissipation of intracellular actions on peripheral organs is unresolved.
fat (Unger, 2002). Since many aspects of leptin defi-
ciency can be reversed by administration of leptin within
the brain (Campfield et al., 1995), or by brain specific Leptin Is Not the Only Adipose Cell Product that
Affects Systemic Metabolismexpression of leptin receptors in receptor deficient mice
(Kowalski et al., 2001), the relative importance of central The adipose cell was previously viewed primarily as a
site for energy to be stored as triglyceride during periodsversus direct peripheral actions of leptin remains uncer-
tain. Although not related directly to the actions of leptin of energy surfeit, and released as free fatty acids and
glycerol during periods of energy need. The discoveryon energy balance, leptin has potent actions on cells of
the immune system (Lord et al., 1998) and the skeleton that absence of the adipocyte hormone leptin produces
severe obesity established the adipocyte as a key endo-(Ducy et al., 2000). It is likely that actions on the immune
system are predominantly direct, whereas, surprisingly, crine gland as well (Ahima and Flier, 2000) (Figure 2).
Many discoveries over the past several years have ex-the actions of leptin on bone may be mediated largely
by changes in sympathetic nerve activity within bone tended this concept, and reveal additional mechanisms
by which altered adipocyte function can translate into(Takeda et al., 2002). An action of leptin to activate the
enzyme AMP kinase in peripheral tissues, which is im- changes in systemic energy balance, or affect the state
of diverse physiologic pathways.portant in regulating the oxidation of lipid fuels, is medi-
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Acrp30/adiponectin is an adipocyte-secreted protein pocyte lipid metabolism can produce systemic changes
that circulates at high concentration (Scherer et al., in metabolic rate that resist obesity. Acyl coenzyme A:
1995). Levels of adiponectin are reduced in obesity, and diacylglycerol acyltransferase 1 (DGAT1) is one of two
the suppression correlates with insulin resistance in known enzymes that catalyze the final step in mamma-
obesity and related disorders (Weyer et al., 2001). Re- lian triglyceride synthesis. DGAT1-deficient mice have
placement of deficient adiponectin has a variety of salu- increased insulin and leptin sensitivity, and increased
tary effects, including reducing glucose and lipid levels, energy expenditure, likely accounting for their protec-
increasing lipid oxidation rates, and reducing vascular tion against diet-induced obesity and insulin resistance
thickening (Berg et al., 2002). Adiponectin appears to (Chen et al., 2002). The leptin-sensitizing effect of
act in part by activating the enzyme AMP kinase (Yama- DGAT1 deficiency is present in both leptin-resistant and
uchi et al., 2002a). Levels are also induced by treatment leptin-deficient genetic models of obesity and may oc-
with antidiabetic thiazoladinediones (Yu et al., 2002). The cur in part by enhancing the effects of leptin in peripheral
cognate receptor for this molecule has recently been tissues. The mechanism for this enhancement is un-
identified (Yamauchi et al., 2003), and the physiologic known. Perilipin coats adipocyte lipid droplets and was
role of this adipocyte hormonal system is receiving great postulated to modulate hydrolysis of triacylglycerol.
attention. Resistin is another adipoctye-secreted pro- Mice with deletion of perilipin are lean with constitutive
tein that was identified as the product of a gene whose activation of adipocyte lipolysis, and they resist obesity
expression in fat was suppressed by treatment with due to high fat diets (Martinez-Botas et al., 2000; Tansey
antidiabetic thiazoladinediones (Steppan et al., 2001). et al., 2001). This resistance to obesity is due to in-
Initial studies suggested that resistin was induced in creased metabolic rate, which is currently unexplained.
obesity and might be in part responsible for systemic Increased systemic exposure to glucocorticoids in-
insulin resistance. An effect of recombinant resistin to duces obesity, but most obese individuals have no such
induce hepatic insulin resistance has been confirmed systemic overexposure. The enzyme 11  Hydroxyste-
(Rajala et al., 2003), although data on its expression in roid dehydrogenase-1 (HSD-1) reactivates glucocorti-
obesity are conflicting (Way et al., 2001), and its cellular coids locally from inactive metabolites, and this enzyme
mechanism of action remains unknown. IL-6 is an im- is expressed within adipose tissue, and is overex-
mune modulating cytokine that is also expressed in fat, pressed in fat in obesity (Rask et al., 2001). Transgenic
and adipocyte expression is increased in obesity. IL-6 overexpression of the enzyme in fat produces obesity,
deficient mice develop late onset obesity that can be with preponderance of the more dangerous visceral fat
prevented by low dose infusion of IL-6 into the brain and a full range of metabolic complications, suggesting
(Wallenius et al., 2002). The extent to which fat-derived a possible role for this enzyme in obesity and its compli-
IL-6 exerts a normal restraint on body fat is unclear at cations (Masuzaki et al., 2001).
this time. In most cases of human obesity, adipocyte
expression of cytokines such as IL-6 and TNF- is in- Gut Signals Also Regulate Energy Balance
creased. The identity of the upstream pathways respon- Well before the discovery of leptin as a peripheral signal
sible for this “inflammatory state” within adipose tissue
of energy stores and energy balance, the gut was known
is a major unanswered question. It seems likely that
as a source of signals that influenced appetite, in partic-
additional adipocyte-secreted factors with systemic im-
ular providing signals to limit individual meals. Since
pact on body weight or obesity complications remain
leptin levels do not rise after meals, it was clear thatto be identified.
leptin is not such a signal. On the other hand, leptinSeveral murine models in which adipocyte function is
deficiency nullifies the efficacy of meal-related signals,selectively altered by changing expression of transcrip-
since individuals lacking leptin have little or no satietytion factors, enzymes, or other proteins are character-
in response to meals. In addition to sensors for stretchized by leanness and/or resistance to obesity. Adipose
that send signals directly to the brain via afferent nerves,selective knockout of the insulin receptor gene pro-
endocrine signals from the gut can regulate appetite.duces lean mice that resist obesity, suggesting that in-
Cholecystokinin (CCK) is the most venerable of these.sulin signaling in adipocytes is necessary for obesity to
CCK is released from the small intestine into the circula-develop (Blu¨her et al., 2002). Foxc2 is a winged helix/
tion in response to luminal nutrients such as fatty acids,forkhead transcription factor whose expression in fat is
and influences satiety by actions on CCK receptors lo-induced by feeding high fat diets. Transgenic overex-
cated on peripheral vagal afferent terminals, whichpression of Foxc2 in fat leads to a lean and insulin sensi-
transmit neural signals to the brainstem (Moran, 2000).tive phenotype (Cederberg et al., 2001). Genetic variabil-
A physiologic role for CCK in the control of meal sizeity at this locus may influence the development of the
has been demonstrated by studies with antagonists,metabolic syndrome (Ridderstrale et al., 2002). Mice het-
and in Otsuka Long Evans Tokushima Fatty rats, whicherozygous for deletion of the PPAR  (Yamauchi et al.,
lack the CCK-A receptor and are obese (Moran et al.,2001; Miles et al., 2000) and CBP (cAMP response ele-
1998).ment binding protein) (Yamauchi et al., 2002b) genes
Three other gut peptides that are released postprandi-are also resistant to the development of obesity and
ally are GIP, GLP-1, and PYY, and recent studies withhave increased insulin sensitivity. Since activation of
each have caused renewed interest in gut factors inPPAR  by antidiabetic thiazoladinedione drugs improves
energy balance. PYY is released from the intestine post-insulin sensitivity, the observation that global PPAR 
prandially in proportion to meal size. Data from rodentshaploinsufficiency improves insulin sensitivity is coun-
and humans suggest that this peptide reduces foodterintuitive, and so far unexplained.
Two additional models suggest that alterations of adi- intake postprandially and may do so by actions on inhibi-
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Figure 3. Leptin-Regulated Hypothalamic
Circuits Are Important for Energy Balance
Leptin acts directly on arcuate nucleus neu-
rons coexpressing NPY and AgRP, and
POMC and CART, via the ObRb form of the
leptin receptor expressed on these cells. The
former neurons stimulate anabolic and orexi-
genic effects and are suppressed by leptin,
and the latter neurons stimulate catabolic and
anorexic actions that promote weight loss,
and are activated by leptin. A key down-
stream target of these neurons are neurons
expressing melanocortin 4 receptors (MC4R)
that are activated by the POMC product 
MSH, and inhibited by the neuropeptide
AgRP. Activation of these neurons promotes
catabolism by reducing food intake and in-
creasing energy expenditure. Neurons ex-
pressing BDNF in the ventromedial hypothal-
amus may be downstream of the MC4R
neurons. Neurons in the lateral hypothalamus
expressing melanin concentrating hormone
(MCH) receive projections from leptin respon-
sive arcuate neurons, and activation of these
widely projecting neurons promotes feeding,
suppresses energy expenditure, and pro-
motes weight gain. These circuits integrate
additional information not illustrated here.
tory presynaptic NPY Y2 receptors present on arcuate other feeding-related neurons has been described (Cowley
et al., 2003). The functional implications of these cellsnucleus NPY neurons (Batterham et al., 2002). Since
PYY levels appear to be reduced in obese individuals are unknown.
after meals and replacement doses of PYY reduce appe-
tite in the obese, therapeutic implications are substantial CNS Integration of Afferent Signals
The hypothalamus is the primary locus for integration(Batterham et al., 2003). GLP-1 is another gut-derived
peptide, also expressed within the brain, that is released of signals that influence energy balance (Figure 3). The
results of genetic studies have revealed the outlines ofpostprandially and produces anorectic effects as well
as symptoms of visceral illness, and activates the sym- several critical hypothalamic circuits. The best defined
of these is the melanocortin pathway (Fan et al., 1997).pathetic nervous system (Yamamoto et al., 2002). GIP
is released from duodenum, predominantly in response This pathway involves neurons within the arcuate nu-
cleus that express proopiomelanocortin (POMC), fromto ingested fat, and mice fed a high fat diet have in-
creased GIP levels and obesity. Mice lacking the GIP which the peptide -MSH is cleaved. Leptin directly
depolarizes and increases POMC expression in thesereceptor are protected against high fat diet-induced
obesity, and Gipr/ mice bred to ob/ob mice are sub- neurons (Cowley et al., 2001). -MSH is an agonist for
a key receptor expressed within the CNS, the melano-stantially less obese (Miyawaki et al., 2002). Thus, GIP
may promote obesity in response to fat. cortin 4 receptor (MC4R) and administration of -MSH
or its analogs centrally suppresses feeding. CompleteGhrelin is a peptide recently found to be made in the
stomach, which acts on a previously identified orphan loss of function of this G protein-coupled receptor
(GPCR) produces obesity in mouse and humans (Huszarreceptor (growth hormone secretagogue receptor), whose
activation in hypothalamus causes growth hormone re- et al., 1997), (Yeo et al., 1998). The pivotal nature of this
pathway is indicated by the fact that haploinsufficiencylease from the pituitary gland (Kojima et al., 1999). This
peptide may be more important for regulating food in- at this locus also causes substantial obesity (Huszar et
al., 1997). Remarkably, the MC4R receives not only thetake and body weight through actions in the arcuate
nucleus, than for growth hormone regulation. Ghrelin is agonist ligand, -MSH, whose expression is induced by
leptin, but also an antagonistic ligand that promotesunique among gut hormones in stimulating food intake,
and its chronic administration to rats causes obesity feeding (AgRP) (Ollmann et al., 1997) whose expression
in a nearby but distinct population of arcuate neurons(Tschop et al., 2000). It has been suggested that ghrelin
levels rise just before spontaneous feeding and may in (that coexpress AgRP and NPY) is diminished by leptin.
Although this pathway is clearly a major leptin-regulatedpart account for meal initiation. The fall in ghrelin levels
after gastric bypass surgery for obesity has been hy- pathway whose output affects appetite, energy expendi-
ture, and metabolic actions in the periphery, the melano-pothesized to in part account for the suppression of
appetite commonly seen after such operations (Cum- cortin pathway is not the only pathway downstream of
leptin, and leptin is not the only factor that regulates themings et al., 2002), although interventional studies re-
placing ghrelin in postsurgical patients are needed to melanocortin pathway. Regarding the latter point, MC4R
pathways appear to be involved in the regulation ofconfirm this. In addition to stomach-derived ghrelin, a
population of hypothalamic ghrelin neurons that contact appetite and body weight mediated through serotonin
Review
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5HT2C receptors (Heisler et al., 2002), activation of Additional CNS Pathways Exist
Several additional hypothalamic pathways that may reg-which causes weight loss and deletion of which causes
ulate energy balance have emerged over the past sev-a syndrome of adult onset obesity in mice. The serotonin
eral years. Bombesin-like peptides are widely distrib-and melanocortin systems may also be relevant to
uted in the CNS and gastrointestinal tract and bind tocachexia (Marks et al., 2001) and perhaps eating disor-
several GPCRs. Mice lacking bombesin receptor sub-ders such as anorexia nervosa.
type-3 develop obesity, hyperphagia, and reduced met-NPY is another neuropeptide whose expression within
abolic rate, as well as impaired glucose metabolism,the arcuate nucleus (coexpressed with AGRP) is linked
indicating a role for this receptor in central control ofto energy balance. Its expression at these sites is nega-
energy balance (Ohki-Hamazaki et al., 1997). Brain de-tively regulated by leptin and insulin, and central NPY
rived neurotrophic factor (BDNF) was initially studiedadministration induces feeding and suppresses energy
for its role in sensory neuron development. BDNF andexpenditure (Billington and Levine, 1992). The numerous
its receptor, TrkB, have been identified in hypothalamicsubtypes of NPY receptors, of which there are at least
neurons associated with satiety. Mice heterozygous for5, and the complex phenotypes observed when antago-
BDNF deficiency are obese and hyperphagic (Kernie etnizing this system either pharmacologically or through
al., 2000), and this can be reversed with central injectiongene knockout (Wieland et al., 2000), has led to some
of BDNF. Obesity is also seen after conditional deletionconfusion about the physiology of this system. Although
of BDNF in brain, suggesting that this neurotrophin may
deletion of the NPY gene partially suppresses the obe-
have regulatory roles in the central energy balance cir-
sity of ob/ob mice (Erickson et al., 1996), normal mice
cuits (Rios et al., 2001). BDNF is highly expressed in the
with combined deletion of both NPY and AgRP suffer ventromedial nucleus (VMN), where its expression is
(Qian et al., 2002) at most very limited deficits in feeding regulated by nutrition and MC4R signaling. BDNF may
or body weight. be an important effector of MC4R signaling (Xu et al.,
2003). Brain histamine has also been implicated in en-
ergy balance circuits, with central histamine administra-
Melanin-Concentrating Hormone tion suppressing food intake and fat accumulation.
In contrast to NPY, melanin-concentrating hormone Leptin has also been shown to modulate central hista-
(MCH) is a key player in another hypothalamic circuit mine turnover, which is reduced in leptin deficient or
for weight regulation that does not readily tolerate dis- resistant mice (Yoshimatsu et al., 1999) . Leptin suppres-
ruption (Figure 3). This peptide is expressed exclusively sion of hypothalamic endocannabinoids anandamide
in large neurons whose cell bodies reside within the and 2-arachidonoyl glycerol has also been implicated in
lateral hypothalamus and zona incerta, an area impli- regulated energy balance (Di Marzo et al., 2001). Acting
cated through lesion studies as a “feeding center.” through CB1 receptors, these endocannabinoids may
These neurons make broad monosynaptic projections mimic the effect of marijuana to stimulate appetite, a
throughout the neuraxis, and MCH receptors are simi- conclusion supported by the phenotype of CB1 receptor
larly widespread. Deletion of the MCH gene produces knockout mice (Cota et al., 2003). VGF is a neuropeptide
a lean and hypophagic mouse with increased energy expressed in hypothalamus, deficiency of which pro-
duces a lean hypermetabolic mouse (Hahm et al., 1999).expenditure (Shimada et al., 1998), and eutopic overex-
Genetic crosses suggest that VGF, which is in part co-pression of MCH produces obesity (Ludwig et al., 2001)
expressed in POMC neurons in the arcuate nucleus, isand susceptibility to a high fat diet. MCH binds to a
downstream of melanocortin 4 receptors that regulateGPCR that is expressed in the brain, and targeted dele-
energy expenditure pathways (Hahm et al., 2002).tion of this receptor (MCHR1) produces a lean mouse
In addition to signals from neuropeptides and neuro-due largely to increased energy expenditure, rather than
cytokines, hypothalamic centers involved in energy ho-suppression of feeding (Marsh et al., 2002). Administra-
meostasis can also be influenced by metabolic sub-tion to mice of an antagonist of this receptor suppresses
strates. Neurons that receive signals from regulatorsfood intake and obesity that develops on a palatable
such as leptin may also sense changes in the levels ofdiet, and has effects as well to reduce behaviors inter-
glucose and free fatty acids. Hypothalamic neurons thatpreted as mouse “anxiety” (Borowsky et al., 2002). A
sense both low and high levels of glucose have beensecond MCHR is found in human but not rodent brain,
identified (Dunn-Meynell et al., 2002). Low glucose (hy-and its function is unknown. Neuroanatomical studies
poglycemia) is well known to induce hunger acutely,
reveal a connection between arcuate neurons express-
and the circuitry underlying this is uncertain. Several
ing POMC and AGRP/NPY and MCH neurons in the lines of evidence combine to suggest that fatty acids and
lateral hypothalamus (Elias et al., 1999). The potential pathways related to fatty acid metabolism may influence
functional relationship between these circuits is being hunger and metabolic pathways through actions in the
evaluated through genetic cross breeding. Deletion of brain. Central administration of an inhibitor of fatty acid
the MCH gene substantially suppresses many aspects synthase (FAS) reduces food intake and body weight
of the ob/ob phenotype (Segal-Lieberman et al., 2003). (Loftus et al., 2000), and it was proposed that buildup
The orexins are two peptides expressed in lateral hypo- of the FAS substrate malonyl CoA might mediate the
thalamic cells distinct from MCH cells. Although these effect, perhaps by inhibiting the mitochondrial enzyme
peptides have effects on feeding, the main role of ore- carnitine palmitoyl transferase I (CPT I) which would
xins appears to be related to sleep, as deficiency of raise cellular levels of long chain acyl CoA derivatives.
orexin or its receptors causes narcolepsy (Mieda and Consistent with this, mice with global deficiency of the
enzyme acetyl CoA carboxylase 2 (ACC2) have de-Yanagisawa, 2002).
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creased levels of malonyl CoA, the product of the en- mechanisms by which taste and smell affect feeding be-
havior.zyme, in several tissues, and display increased rates of
lipid oxidation and hyperphagia, likely due to the ability
of reduced malonyl CoA to disinhibit CPT I, thereby Energy Expenditure
reducing long chain fatty acyl CoA derivatives, and in- The maintenance of energy balance involves coordi-
creasing lipid oxidation rates (Abu-Elheiga et al., 2001). nated changes in energy intake and expenditure, and
Finally, intracerebroventricular administration of the these two limbs of energy balance are physiologically
long chain fatty acid oleic acid suppresses food intake linked, most importantly through hypothalamic circuits.
acutely (Obici et al., 2002a), and genetic or biochemical In most well-identified syndromes of obesity, such as
inhibition of hypothalamic CPT I decreases food intake those involving defects in leptin and the melanocortin
(Obici et al., 2003). It seems likely that key neurons in pathway, obesity results from both increased feeding
the hypothalamus, most likely in the arcuate nucleus, and decreased energy expenditure, suggesting that the
integrate endocrine signals such as leptin with meta- the leptin and melanocortin pathways are upstream of
bolic signals such as glucose and free fatty acids to effector mechanisms that regulate both appetite and
establish a coherent representation of the state of en- energy expenditure. In rodent models, energy expendi-
ergy balance. ture can be directly assessed by measuring oxygen con-
It is evident that our knowledge of the hypothalamic sumption or heat production. A role for defective ther-
signals that influence energy balance is large and grow- mogenesis can be inferred when obesity develops in one
ing, and that the circuitry with the CNS that mediates group of animals despite food intake that is maintained
this system is more complex than initially envisioned. equivalent to a second lean group, a maneuver called
Rather than viewing these hypothalamic pathways as a pair feeding. Although several lines of evidence suggest
simple linear cascade, a systems approach will be that obesity in humans may be in part determined by
needed to fully comprehend the complex regulatory net- reduced energy expenditure (Levine et al., 1999), such
works involved. studies are far more difficult to carry out convincingly
in humans, and molecular insights into the pathways
for reduced energy expenditure in obesity have laggedHedonic Mechanisms for Regulating Feeding
Most of the foregoing discussion has focused upon the behind those related to altered appetite.
Energy expenditure can be viewed as occurring inhomeostatic regulation of energy balance, in which the
control of hunger and satiety promote the unconscious three major categories. The first is the obligatory energy
expended on basic cellular and physiologic functionsmaintenance of adequate stores of energy for short-
term health and long-term survival. Although this ho- that require ATP. The second is the energy expended
in physical activity. The third is referred to as adaptivemeostatic system deserves attention, feeding is also
powerfully influenced by pleasure and reward. The path- thermogenesis, or that component that is stimulated in
response to external stresses such as environmentalways for energy homeostasis must intersect robustly
with these circuits for pleasure and reward (Saper et al., cold or changes in the amount of food ingested, so-
called diet-induced thermogenesis. Adaptive thermo-2002). The neurobiology of taste and smell has seen
tremendous advances, but as yet few insights have genesis requires an uncoupling between fuel oxidation
and biological work, and this could result from the oper-emerged to link these sensory inputs to the pathways
regulating hunger and satiety. Given the powerful and ation of futile cycles, or the creation of proton leak
across the mitochondrial inner membrane that dissi-rapid ability of odors and tastes to stimulate or suppress
our urge to eat, and the increasing ability of the food pates energy stored in the mitochondrial protein electro-
chemical gradient.industry to provide products that stimulate these urges,
the significance and opportunity represented by this Brown adipose tissue is one clear mechanism utilized
by small rodents in particular to induce regulated mito-gap in our knowledge can barely be overestimated. In
addition to taste and smell, brain reward mechanisms, chondrial uncoupling and heat production in response to
both environmental cold temperature and overfeeding.studied most intensively in the context of drug addiction,
are highly relevant to feeding behavior, and ultimately, Triggered by cold exposure, or changes in diet mediated
in part through leptin and melanocortin pathways, cen-the state of energy balance. Interactions between dopa-
minergic, serotonergic, and opioid systems may under- tral sympathetic nervous impulses innervate brown fat
deposits, where norepinephrine acts via  adrenergiclie this circuitry, which involves the nucleus accumbens,
and very likely, direct and indirect relays to the lateral receptors to activate, as well as increase expression
of the mitochondrial uncoupling protein UCP-1. UCP-1hypothalamus (Saper et al., 2002). MCH neurons in the
lateral hypothalamus are well placed to be involved in knockout mice cannot maintain temperature in the cold
(Enerback et al., 1997), and mice with toxigene-inducedthese reward pathways. Further evidence that homeo-
static and hedonic aspects of feeding intersect come deficiency of brown adipose tissue develop obesity
(Lowell et al., 1993). In adult humans, the amount offrom recent observations that food restriction and leptin
have opposite effects to influence reward behavior in a brown adipose tissue is minimal, and UCP-1 expression
is thought to be insufficient to be physiologically mean-well-established model of intracranial self stimulation
(Fulton et al., 2000), and that leptin inhibits sweet sensi- ingful under most circumstances. It was originally
thought that the UCP-1 homologs UCP-2 and UCP-3,tive taste cells in the tongue (Kawai et al., 2000). It seems
evident that future studies of the circuitry of energy which are widely expressed in tissues of rodents and
humans, might provide a common molecular explana-balance that seek to fully explain behavior will need
to incorporate assessment of reward circuitry, and the tion for interindividual differences in thermogenic ca-
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Figure 4. Human Obesity Genes Define a
Pathway for Regulated Energy Balance
Several genes confirmed to play a role in hu-
man obesity define a linear biochemical path-
way for the regulation of energy balance and
body weight. These include leptin, the leptin
receptor, proopiomelanocortin (POMC), pro-
tein convertase 1 (PC1) which is required for
processing POMC to -MSH, and the mela-
nocortin 4 receptor (MC4R). The precise
chemical identity of the MC4R expressing
neurons is unclear, but their output, directly
or indirectly, regulates appetite, energy ex-
penditure, and metabolism.
pacity. Although they resemble UCP-1 in mediating creased energy expenditure of uncertain origin. Several
of these knockouts involve pathways of lipid synthesis.mitochondrial protein leak activity, and their forced over-
expression can increase energy expenditure and reduce Deletion of stearoyl CoA desaturase-1, an enzyme that
desaturates C18 fatty acids, markedly reduces fat massbody fat, they appear not to be critically involved in
whole body energy expenditure, as energy homeostasis and body weight of Lepob/ob mice without reducing their
food intake, but the basis for increased energy expendi-is normal in mice lacking either protein (Arsenijevic et
al., 2000; Vidal-Puig et al., 2000). ture seen in these mice is unclear (Cohen et al., 2002).
Mice deficient in DGAT-1, the enzyme catalyzing theDoes a regulated increase in energy expenditure me-
diated by sympathetic nerves in response to changes final step in mammalian triglyceride synthesis, also re-
sist obesity through increases in energy expenditurein diet, have the capacity to regulate body weight and
fat stores, at least in rodents? Definitive evidence for (Smith et al., 2000), and once again, the link between
the genetic defect and energy expenditure is obscure.this question was recently provided, through develop-
ment of mice with deletion of the three  receptor sub- As stated earlier, deficiency of perilipin leads to leanness
with increased energy expenditure that is not yet ex-types, 1, 2, and 3. When these “betaless” mice are fed
a high fat diet, they develop severe obesity despite food plained. Mice deficient in the MCHR1, which binds a
peptide (MCH), which stimulates feeding and inducesintake identical to wild-type controls (Bachman et al.,
2002). Unlike wild-type mice, betaless mice are unable obesity, resist obesity through increases in energy ex-
penditure, at least in part via physical activity (Marshto increase energy expenditure in response to the calo-
rically dense diet. It is not yet clear whether the site for et al., 2002). This or some other central pathway for
influencing energy expenditure might eventually bediet induced thermogenesis in wild-type mice is limited
to brown adipose tissue, or includes other sites such linked to the observation that individuals resistant to
obesity may engage in physical activity in the form ofas muscle.
Another discovery with potential relevance to regu- fidgeting that can burn calories, currently without expla-
nation (Levine et al., 1999)lated energy expenditure is the identification of the co-
activator protein PGC-1, a mediator of the thermogenic
phenotype in brown fat cells in response to cold expo- Genetic Basis for Obesity and Leanness
The genetic contribution to body fat content in humanssure (Puigserver et al., 1998). This protein can also in-
duce mitochondrial biogenesis (Wu et al., 1999) and is as strong as that for height. Although the search for
genes responsible for human obesity has had somechange the thermogenic state of muscle from white to
red fiber type (Lin et al., 2002). A role for PGC-1 in notable successes, we have not yet accounted for the
genetic explanation for, or susceptibility to obesity indetermining the thermogenic capability of rodents and
humans has not escaped investigators, but published the vast majority of patients. In rare cases of severe
childhood-onset obesity, single gene defects have beenevidence to support this idea is not yet available. How-
ever, PGC-1 dependent transcriptional pathways have identified. These include loss of function mutations in
the genes for leptin, the leptin receptor, proopiomelano-recently been linked to the pathogenesis of Type 2 dia-
betes in humans (Mootha et al., 2003; Patti et al., 2003). cortin (POMC), prohormone convertase 1 (PC1), and the
melanocortin 4 receptor. The latter may account forActivation of the PPAR nuclear transcription factor has
been shown to stimulate fat oxidation and energy expen- 1%–4% of severe early onset obesity. These genes all
encode proteins that act in a central nervous systemditure, perhaps through interaction with PGC-1 (Wang
et al., 2003). Mice deficient in PPAR are prone to obesity pathway for regulation of energy balance (Figure 4). The
responsible genes are still unknown in 95% of severeinduced by high fat diet, and activation of PPAR by
either transgenic or pharmacologic approaches causes early onset obesity, and the fraction of this population
that will eventually be shown to have a Mendelian basismice to have increased rates of fat oxidation and resis-
tance to obesity caused by high fat diet or genetic for obesity is uncertain. In the general population of
adults with obesity, the disorder is certainly mainly poly-changes (Wang et al., 2003).
In a number of rodent models, gene knockouts have genic, with genetic variations creating susceptibility to
environmental factors. Our ability so far to identify suchproduced resistance to obesity associated with in-
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obesity susceptibility genes in the general population and its complications are increasing worldwide, with
major adverse implications for public health. Second,has been limited. Genome wide scans in different ethnic
populations have localized major obesity loci on chro- the recent increase in prevalence is due to changes in
the environment (availability of food, composition ofmosomes 2, 5, 10, 11, and 20 (Clement et al., 2002). It
is possible that a strategy based on identifying genes diet, physical exercise, etc.) rather than changes in the
genome. Third, some individuals, due to genetic inheri-that confer resistance to obesity, or leanness, might
offer an advantage over a search for genes predisposing tance, are more susceptible than others to these conse-
quences. Seeing these facts, some observers stress theto obesity. Another potential approach is the use of
model organisms, such as C. elegans, which lack adi- importance of changing elements of the environment
that promote obesity, viewing this approach as the morepose cells but store energy as lipid droplets in intestinal
cells. Using RNAi, C. elegans genes regulating lipid natural and logical pursuit. This approach is meritorious,
but limited by the fact that the precise nature of thestores have been identified, some of whose homologues
are known participants in mammalian energy balance relevant changes to be recommended is not clear, at
least on the level of public policy, and even if the(e.g., serotonin pathway), and others, although con-
served across animal phylogeny, have not previously changes were clear and supported by data, they would
be difficult to implement. For example, should the entirebeen linked to energy balance, and represent interesting
targets for future study (Ashrafi et al., 2003; McKay et public be advised to ingest low fat diets, as has been
recommended over recent decades, or to pursue dietsal., 2003).
low in rapidly absorbed carbohydrates, as several au-
thorities now recommend (Ludwig, 2002)? Is any singleTargets for Pharmaceutical Development
set of nutritional recommendations appropriate to theExisting approved drugs for treatment of obesity pos-
entire population at risk? To what extent are controlledsess only modest efficacy. Sibutramine blocks presyn-
trials of nutritional recommendations achievable, andaptic uptake of norepinephrine and serotonin, and po-
desirable? How can a desire to have people exercisetentiates the anorectic effects of these neurotransmitters.
more be implemented in a free society in which someOrlistat reduces absorption of dietary fat by inhibiting
people pursue fitness intensively, while many chooseintestinal lipases. Drugs with greater efficacy that are
to exercise as little as possible? How can we reconcilealso safe are needed. Many of the CNS pathways dis-
discordant views within the scientific and public policycussed above have sparked aggressive efforts at phar-
communities on some of these issues, so that a re-maceutical development. These include agonists for the
sponse can be offered to a general public that is starvedmelanocortin 4 receptor, antagonists of the MCHR1 and
for guidance?the ghrelin receptor, and antagonists of the endocan-
Therapeutic approaches based on rational dietary andnabinoid receptor CB1. Additional potential targets with
lifestyle changes must be pursued, and wherever possi-strong rationales include inhibitors of the enzymes 11 
ble, data for the effectiveness of such programs mustHSD-1, PTP1b, and SOCS3.
be obtained. In the meanwhile, it seems logical to exploitAlthough leptin has proven to be of limited efficacy
our recent understanding of the systems regulatingin most obese subjects as a result of leptin resistance,
body weight to develop safe and effective drugs that willthere is substantial interest in the ability of ciliary neuro-
reduce the susceptibility of those most likely to developtrophic factor (CNTF), a neurocytokine with a receptor
obesity and its complications in the world in which wehomologous to the leptin receptor, to have leptin-like
now find ourselves. However much the image of peopleactions in several obesity models, including mice lacking
being medicated to reduce the obesity epidemic mayleptin receptors and those with obesity induced by high
discomfort those who seek a behavioral or public policyfat diets. In rodents, systemic administration of CNTF
remedy, to cease the search for safe and effective medi-activates the JAK STAT pathway in cells in arcuate nu-
cations would be to abandon a major segment of thecleus that overlap with those activated by leptin (Gloa-
population to an unhealthy fate.guen et al., 1997). A modified version of CNTF, termed
Axokine, had promising results in a Phase II study in
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